BNT211 With or Without CARVac Shows Early Activity in CLDN6+ R/R Advanced Solid Tumors
The Claudin-6–directed CAR T-cell therapy, BNT211, showed signs of clinical activity in patients with CLDN6-positive relapsed or refractory solid tumors.
Source: onclive.com